📋 Tender Overview
Eisai Co. Ltd. Headquarters Tokyo CEO Haruo Naito Eisai announced that as part of one strategic investment towards the realization of its medium-term business plan EWAY2025 it has conducted the groundbreaking ceremony for the construction of a new injectionresearch building Eisai Medicine Innovation Technology Solutions EMITS at the Kawashima Industrial Park located in Gifu Prefecture Japan. The current research building at Kawashima Industrial Park has served as a base for formulation research since its completion in 1980. In recent years Eisais drug discovery targets have expanded to include new modalities such as antibodies antibody drug conjugates ADCs and nucleic acid drugs in addition to conventional small molecule compounds. Most of these new modality formulations are injectable thus the utilization of enhanced injection formulation technologies and drug delivery systems DDSs is essential.In order to fulfill the needs for such new modality formulations through EMITS Eisai will transfer its formulation research function from the current research building along with enhancing its manufacturing process development function for injection formulations. In addition Eisai will install an injection manufacturing facility that meets GMP requirements and is aiming for the in-house manufacturing of investigational injection drugs. On top of that there are plans for installation of systems for development of state-of-the-art formulation technology such as liposome and lipid nanoparticle preparations as well as creation of space for collaborative research with external partners. Through these efforts Eisai aims to elevate the quality of the technology and knowledge of its formulation research function and to become a base for disseminating innovation technology and solutions relating to formulations. The completion of the building is scheduled for the second quarter of fiscal year 2022. The Kawashima Industrial Park is Eisais global pharmaceutical manufacturing base at which Eisai has made a comprehensive framework comprising all steps from formulation research to formulation manufacturing. Through the construction of EMITS Eisai aims to elevate the quality of its formulation research and formulation manufacturing accelerate medicine creation activities and ultimately further its contribution to improving the benefits of patients and their families. Good manufacturing practice standards for manufacturing control and quality control.
